跳至主要内容
临床试验/NCT01349452
NCT01349452已完成不适用

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Federal University of São Paulo1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
33
试验地点
1
主要终点
improvement of symptoms of conjunctivitis (pain relief)

研究概览

简要总结

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • onset of symptoms for five days or less
  • eighteen years old or more
  • not pregnant or breastfeeding
  • be able to understand and sign the consent term

排除标准

  • use of antibiotic or corticoid 30 days before
  • monocular vision
  • keratopathy or other ocular diseases

研究组 & 干预措施

Ganciclovir

Experimental

干预措施: Ganciclovir (Drug)

Artificial tear

Sham Comparator

干预措施: Artificial tear (Drug)

结局指标

主要结局

improvement of symptoms of conjunctivitis (pain relief)

时间窗: 6 days

次要结局

未报告次要终点

研究者

发起方
Federal University of São Paulo
申办方类型
Other

研究点 (1)

Loading locations...

相似试验